Form 4: Bain Capital Sells 2M Heartflow Shares

Bain Capital Life Sciences Investors and related entities reported the sale of 2 million shares of Heartflow, Inc. common stock at $28.05 per share, reducing their indirect beneficial ownership to 10,448,158 shares.

Summary

• Bain Capital Life Sciences Investors, LLC, and its affiliated entities, identified as 10% owners and having director representation, sold 2,000,000 shares of Heartflow, Inc. common stock.
• The transaction occurred on February 4, 2026, with each share sold at a price of $28.05.
• Following this sale, the reporting persons indirectly beneficially own 10,448,158 shares of Heartflow, Inc. common stock.
• The beneficial ownership is held directly by BCLS Fund III Investments, LP, with various Bain Capital entities sharing voting and dispositive power.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a moderately negative signal due to the significant sale of shares by a major institutional investor and 10% owner, which could imply a reduced conviction in the company's near-term prospects.

Negatives

• Bain Capital Life Sciences Investors and related entities, who are 10% owners and have director representation, sold a significant block of 2,000,000 shares of Heartflow, Inc. common stock.
• The sale at $28.05 per share represents a reduction in their stake, which can be interpreted as a lack of conviction or a strategic portfolio adjustment by a major institutional investor.

Future Outlook

N/A

Industry Context

StockSavvy.ai notes that insider sales, particularly by significant institutional investors like Bain Capital who also hold director positions, can sometimes signal a shift in their investment strategy or a perceived lack of future upside. While the specific reasons for the sale are not disclosed in a Form 4, such transactions are common for large investors managing their portfolio allocations.

Related Party Transactions

• Bain Capital Life Sciences Investors, LLC and its related entities, who are 10% owners and have director representation, sold 2,000,000 shares of Heartflow, Inc. common stock.

Stakeholder Impact

• Shareholders: May perceive the sale by a major institutional investor and director as a negative signal, potentially influencing market sentiment and the stock price.

Key Dates

Recommendation

The sale of 2,000,000 shares by Bain Capital Life Sciences Investors and its affiliated entities, who are significant 10% owners and have director representation, indicates a notable reduction in their stake. Such a substantial insider sale by a sophisticated institutional investor often signals a lack of conviction in the company's future performance or a belief that the stock is fully valued, prompting a 'sell' recommendation for investors to consider reducing their exposure.

Keywords

Heartflow, HTFL, Bain Capital, insider trading, Form 4, stock sale, beneficial ownership, institutional investor